Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNYSEAMERICAN:APHBNASDAQ:GANXCVE:MPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$2.39+1.3%$2.26$1.11▼$17.88$45.99M1.57508,468 shs333,083 shsAPHBAmpliphi Biosciences$2.17+11.9%$1.74$0.15▼$1.37$72.63MN/A842,200 shs43,768 shsGANXGain Therapeutics$1.60-5.3%$1.86$0.89▼$3.19$50.61M0.12296,427 shs133,597 shsMPHMedicureC$1.23-1.6%C$1.05C$0.63▼C$1.27C$12.84M0.94,035 shs4,050 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio0.00%+13.79%-25.42%+93.12%-78.51%APHBAmpliphi Biosciences0.00%+8.50%+11.86%+69.53%-18.73%GANXGain Therapeutics0.00%-14.21%-11.98%+2.42%+40.83%MPHMedicure0.00%0.00%+6.84%+92.31%+6.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.4995 of 5 stars3.51.00.00.00.01.70.6APHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AGANXGain Therapeutics3.0303 of 5 stars3.65.00.00.02.60.00.6MPHMedicureN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$18.00653.14% UpsideAPHBAmpliphi Biosciences 0.00N/AN/AN/AGANXGain Therapeutics 3.17Buy$8.20412.50% UpsideMPHMedicure 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest ANVS, GANX, MPH, TILS, and APHB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/3/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.006/9/2025ANVSAnnovis BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$30.00 ➝ $12.005/19/2025GANXGain TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$8.00 ➝ $8.005/15/2025ANVSAnnovis BioCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $17.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A$0.67 per shareN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AN/AGANXGain Therapeutics$50K958.40N/AN/A$0.28 per share5.71MPHMedicureC$21.08M0.61C$0.49 per share2.49C$1.91 per share0.64Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$24.59M-$2.16N/AN/AN/AN/A-300.56%-193.50%8/13/2025 (Estimated)APHBAmpliphi BiosciencesN/AN/A0.00∞N/AN/AN/AN/AN/AGANXGain Therapeutics-$20.41M-$0.86N/AN/AN/AN/A-247.55%-146.06%8/6/2025 (Estimated)MPHMedicure-C$2.03M-C$0.19N/A∞N/A-9.65%-10.18%-5.63%N/ALatest ANVS, GANX, MPH, TILS, and APHB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025GANXGain Therapeutics-$0.16-$0.16N/A-$0.16$0.03 millionN/A5/13/2025Q1 2025ANVSAnnovis Bio-$0.47-$0.32+$0.15-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AAPHBAmpliphi BiosciencesN/AN/AN/AN/AN/AGANXGain TherapeuticsN/AN/AN/AN/AN/AMPHMedicureN/A2.24%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A10.6810.68APHBAmpliphi BiosciencesN/AN/AN/AGANXGain Therapeutics0.052.222.22MPHMedicure4.652.031.29Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%APHBAmpliphi BiosciencesN/AGANXGain Therapeutics11.97%MPHMedicure23.10%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio20.80%APHBAmpliphi BiosciencesN/AGANXGain Therapeutics7.18%MPHMedicure26.68%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio319.49 million15.43 millionOptionableAPHBAmpliphi Biosciences3033.47 millionN/ANot OptionableGANXGain Therapeutics2029.95 million27.80 millionOptionableMPHMedicureN/A10.44 millionN/ANot OptionableANVS, GANX, MPH, TILS, and APHB HeadlinesRecent News About These CompaniesMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for The Acquisition of West Olympia PharmacyJune 17, 2025 | finanznachrichten.deEarnings call transcript: Medicure reports Q1 2025 decline in revenue, steady stockMay 24, 2025 | uk.investing.comMedicure, Inc.: Medicure Announces Closing of Purchase Agreement for the Acquisition of Gateway Medical PharmacyMarch 11, 2025 | finanznachrichten.deTyreek Hill was driving an estimated 60 mph in a 40 mph zone before hectic detainment incidentSeptember 12, 2024 | nypost.comNMedicure Inc. (NGQ1.F)August 21, 2024 | uk.finance.yahoo.comMedicure Inc. (MPH.V)August 12, 2024 | ca.finance.yahoo.comMPH:CA Medicure Inc.July 26, 2024 | seekingalpha.comPublic Health (Health Services Administration) MPHMay 25, 2024 | buffalo.eduBMaster of Public Health in Social and Behavioral SciencesMay 12, 2024 | uml.eduURochester, United States - Weather Forecasts | Maps | News - Yahoo WeatherMay 5, 2024 | yahoo.comCluj-Napoca, Romania - Weather Forecasts | Maps | News - Yahoo WeatherApril 24, 2024 | yahoo.comMedicure, Inc.: Medicure Receives US FDA Fast Track Designation for MC-1 for PNPO DeficiencyApril 23, 2024 | finanznachrichten.deLiverpool, United Kingdom - Weather Forecasts | Maps | News - Yahoo WeatherApril 22, 2024 | yahoo.comSofia, Bulgaria - Weather Forecasts | Maps | News - Yahoo WeatherApril 21, 2024 | yahoo.comDallas, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 19, 2024 | yahoo.comPrescott, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 18, 2024 | yahoo.comPortland, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 11, 2024 | yahoo.comOttawa, Canada - Weather Forecasts | Maps | News - Yahoo WeatherApril 11, 2024 | yahoo.comFastest Cars In The World RankedApril 10, 2024 | topspeed.comTOlathe, United States - Weather Forecasts | Maps | News - Yahoo WeatherApril 8, 2024 | yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeANVS, GANX, MPH, TILS, and APHB Company DescriptionsAnnovis Bio NYSE:ANVS$2.39 +0.03 (+1.27%) Closing price 03:59 PM EasternExtended Trading$2.36 -0.03 (-1.26%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Ampliphi Biosciences NYSEAMERICAN:APHB$2.17 +0.23 (+11.86%) As of 07/3/2025AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus (S. aureus) infections; and AB-PA01 for the treatment of pseudomonas aeruginosa (P. aeruginosa) infections. It holds collaborative research and development agreements with the United States Army Medical Research and Materiel Command for the development of bacteriophage therapeutics to treat S. aureus, E. coli, and P. aeruginosa infections; and Walter Reed Army Institute of Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.Gain Therapeutics NASDAQ:GANX$1.60 -0.09 (-5.33%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.08 (+4.69%) As of 06:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. The company's lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase I clinical trials. It also has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of Dementia with Lewy Bodies, Alzhiemer's Disease, Gaucher, GM1 Gangliosidosis, Krabbe Disease, Alpha1-Antitrypsun deficiency, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.Medicure CVE:MPHC$1.23 -0.02 (-1.60%) As of 01:37 PM EasternMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CoreWeave's $9 Billion Power Play for Core Scientific Micron Insiders Sell But Investors Should Buy, Buy, Buy Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up ExxonMobil: Limited Risk and Lots of Reward With This Oil Play D-Wave Is Rising Again Despite Dilution—What’s the Deal? Datadog Joins S&P 500, Triggering a New Wave of Upside MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
